Aurora kinase inhibitor GSK1070916, Purity ≥98%

Synonym: GSK1070916; 942918-07-2; GSK-1070916; GSK-1070916A; GSK 1070916; 3-(4-(4-(2-(3-((Dimethylamino)methyl)phenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl)phenyl)-1,1-dimethylurea; Aurora kinase inhibitor

MDL: MFCD22420815
CAS Number: 942918-07-2
Compound CID: 46885626

Product Size

5 mg; 10 mg; 25 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

GSK1070916, soluble in DMSO and ethanol and insoluble in water, is an Aurora kinase inhibitor that disrupts cell division processes. It targets AuroraC-INCENP, FLT1, Aurora A-TPX2, AuroraB-INCENP, FGFR1, FLT4, SIK, and Tie-2.

Molecular Weight

507.63

Molecular Formula

C₃₀H₃₃N₇O

Targets

AuroraC-INCENP: 6.5 nM; FLT1: 42 nM; Aurora A-TPX2: 1.1 nM; AuroraB-INCENP: 3.5 nM; FGFR1: 76 nM; FLT4: 74 nM; SIK: 70 nM; Tie-2: 59 nM

Form

Lyophilized powder

Purity

≥98%

Solubility

DMSO: 91 mg/mL (179.26 mM); Water: Insoluble; Ethanol: 8 mg/mL (15.75 mM)

Identity

Confirmed by NMR/HPLC/MS.

Stability

The product is stable for three years when stored at the recommended temperature in lyophilized powder.

Applications

GSK1070916 can be utilized to understand the therapeutic potential of Aurora B/C kinase inhibition in cancer models.

Storage

Store at -20ºC.